---
figid: PMC10670368__cancers-15-05384-g002
figtitle: SHP2 is critical in regulating RAS/ERK, PI3K/Akt, and JAK/STAT signaling
  pathways in cancer cells
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10670368
filename: cancers-15-05384-g002.jpg
figlink: /pmc/articles/PMC10670368/figure/F2
number: F2
caption: SHP2 is critical in regulating RAS/ERK, PI3K/Akt, and JAK/STAT signaling
  pathways in cancer cells. These pathways involve cell growth, differentiation, metabolism,
  and apoptosis. SHP2 positively influences the RAS/ERK signaling pathway. Based on
  substrate specificity, SHP2 has a dual role in PI3K/Akt and JAK/STAT pathways
papertitle: 'Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition
  in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches'
reftext: Alireza Tojjari, et al. Cancers (Basel). 2023 Nov;15(22).
year: '2023'
doi: 10.3390/cancers15225384
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: SHP2 | cancer | T-cell | PD-L1 | immunotherapy
automl_pathway: 0.9705986
figid_alias: PMC10670368__F2
figtype: Figure
redirect_from: /figures/PMC10670368__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10670368__cancers-15-05384-g002.html
  '@type': Dataset
  description: SHP2 is critical in regulating RAS/ERK, PI3K/Akt, and JAK/STAT signaling
    pathways in cancer cells. These pathways involve cell growth, differentiation,
    metabolism, and apoptosis. SHP2 positively influences the RAS/ERK signaling pathway.
    Based on substrate specificity, SHP2 has a dual role in PI3K/Akt and JAK/STAT
    pathways
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SERPINA4
  - PTPN11
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ARHGEF2
  - SLC2A4RG
  - IL6
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - PRDX1
  - PAG1
  - CREBBP
  - EIF4E
  - OPN1LW
  - PCBP4
  - CSK
  - SPRY1
  - SPRY2
  - SPRY3
  - SPRY4
  - RASA1
  - KRAS
  - NRAS
  - MTOR
  - APP
  - AAAS
  - AAA1
  - HRAS
  - SRC
  - FGR
  - FYN
  - YES1
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - SOCS1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - Erlotinib
  - Paxillin
  - Aaa
  - Ras
  - Dabrafenib
  - MEK
  - Trametinib
---
